KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested Capital

AbCellera Biologics (ABCL) EBT Margin (2020 - 2023)

AbCellera Biologics' EBT Margin history spans 4 years, with the latest figure at 529.49% for Q4 2023.

  • For the quarter ending Q4 2023, EBT Margin fell 38369.0% year-over-year to 529.49%, compared with a TTM value of 457.66% through Dec 2023, down 50692.0%, and an annual FY2024 reading of 695.02%, down 23735.0% over the prior year.
  • EBT Margin for Q4 2023 was 529.49% at AbCellera Biologics, up from 595.18% in the prior quarter.
  • The five-year high for EBT Margin was 79.65% in Q1 2021, with the low at 595.18% in Q3 2023.
  • Average EBT Margin over 4 years is 137.27%, with a median of 21.88% recorded in 2022.
  • Year-over-year, EBT Margin soared 49933bps in 2022 and then plummeted -64113bps in 2023.
  • Tracing ABCL's EBT Margin over 4 years: stood at 77.52% in 2020, then dropped by -22bps to 60.8% in 2021, then plummeted by -340bps to 145.8% in 2022, then plummeted by -263bps to 529.49% in 2023.
  • Per Business Quant, the three most recent readings for ABCL's EBT Margin are 529.49% (Q4 2023), 595.18% (Q3 2023), and 377.92% (Q2 2023).